These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 20886392)

  • 21. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
    Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q
    Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus vaccine development.
    Fife KH
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S8-10. PubMed ID: 9842094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
    Mahdavi A; Monk BJ
    Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human papillomavirus vaccines for the treatment of cervical cancer.
    Sin JI
    Expert Rev Vaccines; 2006 Dec; 5(6):783-92. PubMed ID: 17184217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
    Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.
    Daayana S; Elkord E; Winters U; Pawlita M; Roden R; Stern PL; Kitchener HC
    Br J Cancer; 2010 Mar; 102(7):1129-36. PubMed ID: 20234368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
    Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
    Nimako M; Fiander AN; Wilkinson GW; Borysiewicz LK; Man S
    Cancer Res; 1997 Nov; 57(21):4855-61. PubMed ID: 9354449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
    Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
    Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
    Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
    Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine.
    de Jong A; O'Neill T; Khan AY; Kwappenberg KM; Chisholm SE; Whittle NR; Dobson JA; Jack LC; St Clair Roberts JA; Offringa R; van der Burg SH; Hickling JK
    Vaccine; 2002 Oct; 20(29-30):3456-64. PubMed ID: 12297390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).
    Davidson EJ; Faulkner RL; Sehr P; Pawlita M; Smyth LJ; Burt DJ; Tomlinson AE; Hickling J; Kitchener HC; Stern PL
    Vaccine; 2004 Jul; 22(21-22):2722-9. PubMed ID: 15246603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization and evaluation of the immune responses elicited by a novel human papillomavirus (HPV) therapeutic vaccine: HPV 16E7-HBcAg-Hsp65 fusion protein.
    Zhou CM; Zhang GX; Ma XX
    J Virol Methods; 2014 Mar; 197():1-6. PubMed ID: 24291739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice.
    Bian T; Wang Y; Lu Z; Ye Z; Zhao L; Ren J; Zhang H; Ruan L; Tian H
    Mol Cancer Ther; 2008 May; 7(5):1329-35. PubMed ID: 18483320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3.
    Park YC; Ouh YT; Sung MH; Park HG; Kim TJ; Cho CH; Park JS; Lee JK
    J Gynecol Oncol; 2019 Nov; 30(6):e88. PubMed ID: 31576684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia.
    Frazer IH; Quinn M; Nicklin JL; Tan J; Perrin LC; Ng P; O'Connor VM; White O; Wendt N; Martin J; Crowley JM; Edwards SJ; McKenzie AW; Mitchell SV; Maher DW; Pearse MJ; Basser RL
    Vaccine; 2004 Nov; 23(2):172-81. PubMed ID: 15531034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient: a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials.
    Werner RN; Westfechtel L; Dressler C; Nast A
    Sex Transm Infect; 2017 Dec; 93(8):543-550. PubMed ID: 28637906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant effect of docetaxel on HPV16 L2E6E7 fusion protein vaccine in a mouse model.
    Su X; Xu W; Guan R; Wang Y; Wu J; Zhai L; Chen G; Hu S
    Int Immunopharmacol; 2016 Sep; 38():16-25. PubMed ID: 27233002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.